StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab operating margin

Operating margin is operating income as a percentage of revenue.

BioNexus Gene Lab's operating margin for the twelve months ending Jun 30, 2026 was -81.8%. For fiscal 2025 it was -39.9%, against -16.5% the year before. The highest annual figure on record is 28.2% in fiscal 2018.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-39.9%−23.4
FY2024Dec 31, 2024-16.5%+10.0
FY2023Dec 31, 2023-26.5%−23.9
FY2022Dec 31, 2022-2.7%−10.6
FY2021Dec 31, 20217.9%−3.3
FY2020Dec 31, 202011.2%+228.4
FY2019Dec 31, 2019-217.2%−245.4
FY2018Dec 31, 201828.2%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-370.8%−343.8
Q1 FY2026Mar 31, 2026-2366.2%−2337.3
Q4 FY2025Dec 31, 2025-213.5%−197.0
Q3 FY2025Sep 30, 2025-27.6%+23.2
Q2 FY2025Jun 30, 2025-27.0%−40.2
Q1 FY2025Mar 31, 2025-28.9%−25.6
Q4 FY2024Dec 31, 2024-16.5%−27.8
Q3 FY2024Sep 30, 2024-50.9%+48.2
Q2 FY2024Jun 30, 202413.1%+23.7
Q1 FY2024Mar 31, 2024-3.3%−1.2
Q4 FY2023Dec 31, 202311.3%+15.7
Q3 FY2023Sep 30, 2023-99.0%−96.5
Q2 FY2023Jun 30, 2023-10.6%−5.1
Q1 FY2023Mar 31, 2023-2.1%−3.3
Q4 FY2022Dec 31, 2022-4.3%−10.5
Q3 FY2022Sep 30, 2022-2.5%−13.0
Q2 FY2022Jun 30, 2022-5.6%−10.1
Q1 FY2022Mar 31, 20221.1%−8.8
Q4 FY2021Dec 31, 20216.2%+6.3
Q3 FY2021Sep 30, 202110.4%+2.7
Q2 FY2021Jun 30, 20214.5%+7.6
Q1 FY2021Mar 31, 20219.9%−25.0
Q4 FY2020Dec 31, 2020-0.1%+181.2
Q3 FY2020Sep 30, 20207.7%+215.1
Q2 FY2020Jun 30, 2020-3.1%+316.7
Q1 FY2020Mar 31, 202035.0%+249.3
Q4 FY2019Dec 31, 2019-181.2%+492.2
Q3 FY2019Sep 30, 2019-207.4%−147.2
Q2 FY2019Jun 30, 2019-319.8%−284.3
Q1 FY2019Mar 31, 2019-214.3%–
Q4 FY2018Dec 31, 2018-673.4%–
Q3 FY2018Sep 30, 2018-60.2%–
Q2 FY2018Jun 30, 2018-35.5%–

More BioNexus Gene Lab figures

See a number that looks wrong?